Journal
CLINICAL ONCOLOGY
Volume 24, Issue 3, Pages 216-227Publisher
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.clon.2011.06.004
Keywords
Glioblastoma; MRI; pseudoprogression; temozolomide
Categories
Funding
- Schering Plough Ltd.
- Merck Sharp Dohme Ltd.
Ask authors/readers for more resources
Since postoperative radiotherapy plus concomitant temozolomide followed by adjuvant temozolomide has become standard treatment for glioblastoma, the phenomenon of early post-treatment enlargement of the imaged tumour volume, usually without clinical deterioration, has become widely recognised. The term pseudoprogression has been used to describe a poorly understood pathophysiological process. In this review, the pathophysiological concepts, relevance, diagnosis and management of patients with 'pseudoprogression' and 'pseudoresponse' are discussed. Guidelines are given with respect to radiological imaging modality, mode and frequency. Further biological and clinical insights into these phenomena require carefully designed prospective studies. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available